文献速递分子诊断临床微生物

一体化微流控扩增微阵列检测原痰与去污沉渣中耐多药结核分枝杆菌的基因分型

Genotyping Multidrug-Resistant Mycobacterium tuberculosis from Primary Sputum and Decontaminated Sediment with an Integrated Microfluidic Amplification Microarray Test.
PubMed 文献 · J Clin Microbiol · 2018-02-22

研究将开放扩增子微阵列杂交试验改造为全封闭扩增子微阵列,用配对的痰液和沉渣提取物评估其对耐多药结核分枝杆菌的基因分型性能。结果显示可重复基因分型的检测限约为每个反应25个结核分枝杆菌基因组,痰提取物检出率99.1%,沉渣100%,与实时PCR 100%一致。与原痰相比沉渣基因分型结果100%一致,对利福平耐药检测特异性97.1%、敏感性75.0%。

要点

  • 检测限约25个基因组(100 fg DNA)/反应,4°C保存货架期至少18个月。
  • 痰与沉渣提取物基因分型结果100%一致,推荐原痰为首选标本。
  • 利福平耐药检测特异性97.1%、敏感性75.0%;异烟肼耐药特异性98.4%(痰)和96.8%(沉渣)、敏感性63.6%。

核心结论

  • 封闭扩增子微阵列可对原痰和去污沉渣提取物中的耐多药结核分枝杆菌进行可重复基因分型,原痰可考虑作为首选标本。

研究设计与样本

  • 将开放扩增子微阵列杂交试验改造为全封闭扩增子微阵列,并用配对的痰液和沉渣提取物评估其性能。

主要发现

  • 可重复基因分型的检测限约为每个反应25个结核分枝杆菌基因组(100 fg DNA)。
  • 4°C储存时估计货架期至少18个月。
  • 痰提取物中结核分枝杆菌检出率99.1%,沉渣提取物100%,与实时PCR结果100%一致。
  • 痰和沉渣提取物中结核分枝杆菌与耐药相关基因检测的一致率分别为99.1%和98.4%。
  • 痰与沉渣提取物之间基因分型结果100%一致。

关键数值与推荐

  • 与培养药敏试验相比,痰和沉渣提取物检测利福平耐药的特异性为97.1%,敏感性为75.0%。
  • 痰和沉渣提取物检测异烟肼耐药的特异性分别为98.4%和96.8%,敏感性为63.6%。
  • 扩增微阵列对所有不一致的表型/基因型结果均报告了正确基因型。

临床怎么用

  • 原痰可考虑作为该检测的首选标本。
  • 该扩增微阵列设计、货架期和分析性能指标与下一代耐药结核诊断共识产品特征高度一致,且较其他基于杂交的耐多药结核检测更易使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is a growing awareness that molecular diagnostics for detect-to-treat applications will soon need a highly multiplexed mutation detection and identification capability. In this study, we converted an open-amplicon microarray hybridization test for multidrug-resistant (MDR) Mycobacterium tuberculosis into an entirely closed-amplicon consumable (an amplification microarray) and evaluated its performance with matched sputum and sediment extracts. Reproducible genotyping (the limit of detection) was achieved with ∼25 M. tuberculosis genomes (100 fg of M. tuberculosis DNA) per reaction; the estimated shelf life of the test was at least 18 months when it was stored at 4°C. The test detected M. tuberculosis in 99.1% of sputum extracts and 100% of sediment extracts and showed 100% concordance with the results of real-time PCR. The levels of concordance between M. tuberculosis and resistance-associated gene detection were 99.1% and 98.4% for sputum and sediment extracts, respectively. Genotyping results were 100% concordant between sputum and sediment extracts. Relative to the results of culture-based drug susceptibility testing, the test was 97.1% specific and 75.0% sensitive for the detection of rifampin resistance in both sputum and sediment extracts. The specificity for the detection of isoniazid (INH) resistance was 98.4% and 96.8% for sputum and sediment extracts, respectively, and the sensitivity for the detection of INH resistance was 63.6%. The amplification microarray reported the correct genotype for all discordant phenotype/genotype results. On the basis of these data, primary sputum may be considered a preferred specimen for the test. The amplification microarray design, shelf life, and analytical performance metrics are well aligned with consensus product profiles for next-generation drug-resistant M. tuberculosis diagnostics and represent a significant ease-of-use advantage over other hybridization-based tests for diagnosing MDR tuberculosis.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Linger Y, Knickerbocker C, Sipes D, et al. Genotyping Multidrug-Resistant Mycobacterium tuberculosis from Primary Sputum and Decontaminated Sediment with an Integrated Microfluidic Amplification Microarray Test. J Clin Microbiol. 2018. PMID: 29305543. doi:10.1128/JCM.01652-17

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。